Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe.The findings in this study do not suggest an association between COVID-19 vaccination and overall increased rates of death. Synopsis: The authors of this study analyzed VAERS reports of death after COVID-19 vaccination and found that rates of death after vaccination were lower than background rates of death from any cause in the general population.
Reporting Rates for VAERS Death Reports Following COVID-19 Vaccination, December 14, 2020-November 17, 2021. The authors determined that there is no increased risk of death among COVID-19 vaccine recipients, reinforcing the safety of COVID-19 vaccines currently authorized for use in the United States. Synopsis: Using data from the Vaccine Safety Datalink (VSD), this study found that rates of death among people who received COVID-19 vaccines were lower than those of people who did not receive COVID-19 vaccines. COVID-19 Vaccination and Non-COVID-19 Mortality Risk-Seven Integrated Health Care Organizations, United States, December 14, 2020-July 31, 2021. In the largest study of its kind to date, the authors found no increased risk of death among people who received the Pfizer-BioNTech, Moderna, or Johnson and Johnson’s Janssen (J&J/Janssen) COVID-19 vaccines. Synopsis: This study found that rates of death among people who received COVID-19 vaccines were lower than those of people who did not receive COVID-19 vaccines. A Safety Study Evaluating Non-COVID-19 Mortality Risk Following COVID-19 Vaccination. No deaths from anaphylaxis were reported. In nine of those cases, anaphylaxis symptoms began within 15 minutes of vaccination. Synopsis: From December 21, 2020, through January 10, 2021, CDC safety monitoring of the Moderna COVID-19 vaccine in VAERS identified 10 cases of anaphylaxis from a reported 4,041,396 first doses of the vaccine, corresponding to an estimated 2.5 cases per million doses administered. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine- United States, December 21, 2020-January 10, 2021. Continued safety monitoring of mRNA COVID-19 vaccines has confirmed that anaphylaxis following vaccination is rare. 
Synopsis: From December 14, 2020, through January 18, 2021, CDC safety monitoring of mRNA COVID-19 vaccines in VAERS identified 66 reports of anaphylaxis: 47 cases following receipt of the Pfizer-BioNTech vaccine and 19 cases following receipt of the Moderna vaccine. Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021.Synopsis: CDC and FDA safety monitoring of the Pfizer-BioNTech COVID-19 vaccine in the Vaccine Adverse Event Reporting System (VAERS) identified 21 reports of anaphylaxis from the 1.89 million first doses of the vaccine administered from December 14 through 23, 2020, corresponding to an estimated rate of 11.1 cases per million doses administered 17 of those cases (81%) had a history of allergies or allergic reactions. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine.
0 kommentar(er)
